| PSTV Stock | | | USD 1.26 0.03 2.44% |
Plus Therapeutics financial indicator trend analysis is much more than just breaking down Plus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Plus Therapeutics is a good investment. Please check the relationship between Plus Therapeutics Cash Per Share and its Pb Ratio accounts. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
For more information on how to buy Plus Stock please use our
How to Invest in Plus Therapeutics guide.
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Plus Therapeutics Cash Per Share account and
Pb Ratio. At this time, the significance of the direction appears to have weak relationship.
The correlation between Plus Therapeutics' Cash Per Share and Pb Ratio is 0.37. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Pb Ratio in the same time period over historical financial statements of Plus Therapeutics, assuming nothing else is changed. The correlation between historical values of Plus Therapeutics' Cash Per Share and Pb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Plus Therapeutics are associated (or correlated) with its Pb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pb Ratio has no effect on the direction of Cash Per Share i.e., Plus Therapeutics' Cash Per Share and Pb Ratio go up and down completely randomly.
Correlation Coefficient | 0.37 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Most indicators from Plus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
For more information on how to buy Plus Stock please use our
How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics'
Selling General Administrative is fairly stable compared to the past year.
Issuance Of Capital Stock is likely to climb to about 9.1
M in 2025, despite the fact that
Discontinued Operations is likely to grow to (6.5
M).
When running Plus Therapeutics' price analysis, check to
measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.